Pfizer Corporation

Edward Raymond Guilmette

Chakrapani Subramanyam

Jotham Wadsworth Coe

Christopher John Helal

Scot Richard Mente

Jennifer Elizabeth Davoren

Ivan Viktorovich Efremov

Steven Victor O'Neil

Amy Beth Dounay

David Lawrence Firman Gray

Jaclyn Louise Henderson

Chris John Helal

John Arthur Allen

Anthony Richard Harris

Deane Milford Nason

Wenjian Xu

Steven Victor O'neil

David Lawrence Gray

Deane Milford Ii Nason

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced &#x3b2;-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

Heteroaromatic compounds and their use as dopamine D1 ligands

Growing community of inventors

Franklin, MA, United States of America

Edward Raymond Guilmette